Astex announces exclusive research collaboration and license agreement with Genentech for breast cancer therapy program

Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, today announces that it has entered into an exclusive, worldwide research collaboration and license agreement with Genentech, a member of the Roche Group, to identify small molecule drug candidates with selective inhibitory activity as potential treatments for breast cancer.

Under the terms of the agreement, Astex will grant Genentech an exclusive license to compounds from Astex’s existing drug discovery program for breast cancer and will collaborate with Genentech to accelerate the further optimisation and development of lead compounds towards the identification of preclinical candidates. Genentech will be solely responsible for preclinical and clinical development of lead candidates as well as commercialisation of all medicines arising from the collaboration globally. Astex will receive an upfront payment of $25 million and is eligible to receive further payments on the achievement of preclinical, clinical, regulatory and sales milestones, potentially totalling more than $490 million, as well as tiered royalties on net sales of medicines arising from the collaboration.      

Astex’s drug discovery program originated from an earlier collaborative project under Astex’s strategic alliance agreement with Newcastle University and Cancer Research Horizons. 

Michelle Jones, president of Astex Pharmaceuticals, said:

Working together with colleagues from Newcastle University, Astex’s fragment-based drug discovery expertise has led to the discovery of a novel and innovative approach to selectively inhibit this key oncology target for breast cancer therapy. Genentech’s focus on embracing innovation, its expertise in oncology and its longstanding dedication to innovation for breast cancer patients makes Genentech an excellent partner for this collaboration. We are delighted to be working together in this important drug discovery alliance with the aim to build on our progress and accelerate compounds into development in a rapidly emerging area of need which, as yet, remains unmet.

Boris L. Zaïtra, Head of Roche Corporate Business Development, said:

We are committed to pushing the boundaries of scientific innovation and turning breakthroughs into better outcomes for people with breast cancer. Working alongside partners like Astex Pharmaceuticals in pursuit of precision therapies against cell-cycle regulators, we follow the science to focus our innovation on the areas of the highest unmet need.